![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
DD Christ, PC Wong, YN Wong, SD Hart, CY Quon and GN Lam
Drug Metabolism and Pharmacokinetics Section, DuPont Merck Pharmaceutical Company, Wilmington, Delaware.
The pharmacokinetics and plasma concentration-effect relationship for the nonpeptide angiotensin II (Ang II) receptor antagonist losartan potassium (losartan) have been determined with conscious and anesthetized dogs. The p.o. bioavailability of single doses of 5 to 20 mg/kg was low, 23 to 33%, and independent of the dose. Absorption was rapid, with peak plasma levels observed within 1 hr, and the Cmax and area under the concentration vs. time curve to infinity were proportional to the dose, P < .05. The elimination half-life, 108 to 153 min, was longer than that observed after a single i.v. dose, 41 min, and may reflect both continuous absorption and enterohepatic recirculation because the major route of excretion was via the bile. Single i.v. doses were eliminated rapidly, with a systemic plasma clearance of 22.2 ml/min/kg. When corrected for the blood:plasma distribution ratio, 0.66 to 0.72, the systemic clearance approximates hepatic blood flow, suggesting that clearance is primarily via hepatic metabolism and biliary excretion. Losartan was not distributed extensively to tissues; apparent volume of distribution at steady-state of 0.30 liters/kg and was highly but not extensively bound to plasma proteins; 2.7 to 2.9% unbound (free). The plasma concentration vs. blockade of exogenous Ang II-induced vasopressor response was also determined after a single 3-mg/kg i.v. dose of losartan with a sigmoidal Emax model. Blockade of the pressor response was rapid, 89% at 5 min, and declined to 11% at 240 min postdose. The relationship between concentration and effect was highly significant (r = 0.922, P < .01), with an IC50 (total) of 96 ng/ml.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  O. Picker, L. A. Schwarte, H. J. Roth, J. Greve, and T. W. L. Scheeren Comparison of the role of endothelin, vasopressin and angiotensin in arterial pressure regulation during sevoflurane anaesthesia in dogs Br. J. Anaesth., January 1, 2004; 92(1): 102 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Davi, C. Tronquet, G. Miscoria, L. Perrier, P. DuPont, J. Caix, J. Simiand, and Y. Berger Disposition of Irbesartan, an Angiotensin II AT1-Receptor Antagonist, in Mice, Rats, Rabbits, and Macaques Drug Metab. Dispos., January 1, 2000; 28(1): 79 - 88. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. J. Lynch Jr., G. L. Stump, A. A. Wallace, C. A. Painter, J. M. Thomas, S. E. Kusma, R. J. Gould, and W. Grossman EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction J. Am. Coll. Cardiol., September 1, 1999; 34(3): 876 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ma, H. D. Schultz, and W. Wang Chronic central infusion of ANG II potentiates cardiac sympathetic afferent reflex in dogs Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H15 - H22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Krebs, W. Boemke, S. Simon, M. Wenz, and G. Kaczmarczyk Acute hypoxic pulmonary vasoconstriction in conscious dogs decreases renin and is unaffected by losartan J Appl Physiol, June 1, 1999; 86(6): 1914 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Krebs, T. Krohn, W. Boemke, R. Mohnhaupt, and G. Kaczmarczyk Renal and hemodynamic effects of losartan in conscious dogs during controlled mechanical ventilation Am J Physiol Renal Physiol, March 1, 1999; 276(3): F425 - F432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Munter, H. Ehmke, and M. Kirchengast Maintenance of blood pressure in normotensive dogs by endothelin Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1022 - H1027. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
